Treatment

Semaglutide Pen Injector clinical trials

Active studies that list Semaglutide Pen Injector as an intervention or treatment.

9active studies

8recruiting now

3countries represented

13largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

GLP-1R Agonist Treatment for Opioid Use Disorder

Opioid Use Disorder, Opioid Abuse and AddictionCondition

Semaglutide Pen Injector, PlaceboTreatment

United States4 locations

Milton S. Hershey Medical CenterSponsor

Updated 2026-08-28 · NCT06548490See eligibility →

Recruiting nowPhase 2

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Diabetes type1, ObesityCondition

Semaglutide Pen Injector, PlaceboTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-08-04 · NCT06411210See eligibility →

Recruiting nowPhase 3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Glucose Intolerance After a Recent History of Gestational DiabetesCondition

Semaglutide Pen Injector, Semaglutide placeboTreatment

Belgium13 locations

Universitaire Ziekenhuizen KU LeuvenSponsor

Updated 2026-07-07 · NCT05569772See eligibility →

Recruiting nowPhase 2

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NAFLDCondition

Semaglutide Pen Injector, PlaceboTreatment

United States1 locations

University of VirginiaSponsor

Updated 2026-06-04 · NCT05424003See eligibility →

Recruiting nowPhase 1, Phase 2

Feasibility of Semaglutide in Advanced Lung Disease

Obesity, Interstitial Lung DiseaseCondition

Semaglutide Pen InjectorTreatment

United States1 locations

University of PennsylvaniaSponsor

Updated 2026-04-21 · NCT05746039See eligibility →

Recruiting nowPhase 3

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Diabetes Mellitus, Type 1Condition

Semaglutide Pen Injector, PlaceboTreatment

United States2 locations

University of Colorado, DenverSponsor

Updated 2026-03-04 · NCT05819138See eligibility →

Recruiting nowPhase 4

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Obesity (Disorder)Condition

Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)Treatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-01-14 · NCT06852391See eligibility →

Recruiting nowPhase 4

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Prostate CancerCondition

Semaglutide Pen InjectorTreatment

Canada1 locations

Hamilton Health Sciences CorporationSponsor

Updated 2025-07-29 · NCT06908694See eligibility →

Active, not recruitingPhase 2

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

Type 2 Diabetes Mellitus, Impaired Glucose ToleranceCondition

Semaglutide Pen Injector, PlaceboTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-04-15 · NCT05067621See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.